Neovascular age-related macular degeneration (nAMD) demands consistent anti-VEGF therapy, but faricimab for nAMD care presents a transformative approach for overburdened clinics. Indeed, faricimab for nAMD care offers long-term durability that reduces treatment frequency. Consequently, healthcare providers can now address capacity constraints more effectively. Moreover, recent data from a UK-based microsimulation model highlight how faricimab enhances service delivery. In addition, this performance significantly exceeds that of biosimilar aflibercept 2 mg.

The Operational Advantages of Faricimab for nAMD Care

Specifically, the study demonstrated that faricimab slashed delayed visits by 97.4% in the base case analysis. Furthermore, loading phase completion improved by 54.1 percentage points. Therefore, more patients receive the full initial treatment necessary for vision preservation. Similarly, the research compared two different payer strategies. For example, a "treatment choice" policy yielded better operational metrics than a "strict biosimilar mandate." Thus, allowing clinicians to choose durable options leads to higher care quality.

Notably, faricimab showed lower acquisition costs than competitors. In contrast, the therapy generated additional savings through reduced service utilization. Ultimately, these efficiencies allow health systems to treat more patients. As a result, clinics can maintain higher standards while lowering costs. Because faricimab requires fewer injections, it also reduces litigation-related expenses. In conclusion, durable therapies provide both clinical and economic value and enhance sustainability.

Frequently Asked Questions

How does faricimab for nAMD care improve clinic efficiency?

Faricimab improves efficiency by extending the interval between injections, which reduces the total number of patient visits and frees up clinical staff to treat more individuals.

What was the impact on treatment delays in the study?

The simulation model showed that using faricimab reduced delayed visits by over 97% compared to biosimilar aflibercept 2 mg in a capacity-constrained setting.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. While we strive for accuracy, healthcare professionals should always verify information with primary sources. Refer to the latest local and national guidelines for clinical practice.

References

Gil-Rojas Y et al. Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care. Ophthalmol Ther. 2026 Mar 19. doi: 10.1007/s40123-026-01346-9. PMID: 41854807.

Roche Pharma India. Roche Pharma Introduces Vabysmo To Treat Vision Impairment in the Indian Market. March 2024.

Heier JS et al. Efficacy, durability, and safety of faricimab in neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022; 399(10326):729-740.